Murine RANK-human immunoglobulin fusion protein
Alternative Names: gkB-IgG Fc fusion protein; muRANK.FcLatest Information Update: 10 Sep 2008
Price :
$50 *
At a glance
- Originator Amgen
- Developer Amgen; University of Texas Health Science Center at San Antonio
- Class Immunoglobulin fusion proteins
- Mechanism of Action Osteoclast inhibitors; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant hypercalcaemia
Most Recent Events
- 10 Sep 2008 Discontinued - Preclinical for Malignant hypercalcaemia in USA (Parenteral)
- 24 Jul 2002 Immunex has been acquired by, and merged into, Amgen
- 26 Jun 2001 Preclinical development for Malignant hypercalcaemia in USA (Unknown route)